{"id":803123,"date":"2026-08-05T04:30:10","date_gmt":"2026-08-05T04:30:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/803123\/"},"modified":"2026-08-05T04:30:10","modified_gmt":"2026-08-05T04:30:10","slug":"eli-lilly-to-offer-experimental-glp-1-retatrutide-for-compassionate-use-who-qualifies","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/803123\/","title":{"rendered":"Eli Lilly to Offer Experimental GLP-1 Retatrutide for Compassionate Use \u2014 Who Qualifies?"},"content":{"rendered":"

Eli Lilly, the drugmaker behind the GLP-1 drugs Mounjaro and Zepbound, will allow a limited number of adults with severe obesity<\/a> to seek early access to retatrutide<\/a>, its experimental weight loss drug, according to original reporting from STAT, a health and life science news publication.<\/p>\n

[1]<\/p>\n

The decision comes after STAT revealed that the company had provided the unapproved medication to an anonymous 79-year-old adult through a \u201ccompassionate use\u201d pathway allowed by the U.S. Food and Drug Administration (FDA).<\/p>\n

This doesn\u2019t mean retatrutide is now broadly available to the public. The once-weekly injection, which targets three hormone receptors in the body \u2014\u00a0GLP-1, GIP, and glucagon \u2014 is still in clinical trials, and FDA approval isn\u2019t expected until sometime next year.<\/p>\n

[1]<\/p>\n

[2]<\/p>\n

Retatrutide Has Produced Unprecedented Weight Loss in Trials<\/p>\n

Interest in early access to retatrutide is high because the drug has produced striking weight loss<\/a> in studies. \u201cWe are all eagerly awaiting FDA approval of retatrutide, which has shown unprecedented weight loss results in clinical trials,\u201d says Sun Kim, MD<\/a>, an associate professor of medicine and an endocrinologist at Stanford Health Care in California.<\/p>\n

In phase 3 results released by Lilly, people who took the highest dose of retatrutide lost 25 percent of their starting weight on average, over 80 weeks, when the analysis included participants who dropped out of the study early. In an analysis estimating the effect on only the participants who remained on treatment, average weight loss reached 28.3 percent.<\/p>\n

[3]<\/p>\n

For context, separate pivotal trials found an average weight loss of about 15 percent with semaglutide (Wegovy)<\/a> over 68 weeks and nearly 21 percent with tirzepatide (Zepbound)<\/a> over 72 weeks. These studies did not directly compare all of these drugs, so the figures do not prove that retatrutide is more effective.<\/p>\n

[4]<\/p>\n

[5]<\/p>\n

How Does the FDA Define \u2018Compassionate Use,\u2019 and Who Might Qualify?Expanded access, also called compassionate use, allows someone with a serious or life-threatening condition to receive an experimental drug outside a clinical trial. The FDA says compassionate use may be considered when:<\/p>\n

[6]<\/p>\n

There is no satisfactory treatment for the patient\u2019s condition.The person cannot join a trial.The possible benefit justifies the risks.Providing the drug will not interfere with its development.<\/p>\n

\u201cCompassionate use is an important pathway for patients with life-threatening conditions such as advanced cancer or severe infectious diseases, but the application process is complex and time-consuming,\u201d says Dr. Kim.<\/p>\n

While obesity is associated with major health risks, its complications are generally less immediate, making compassionate use more difficult to justify under current standards, she says.<\/p>\n

According to Lilly, to qualify for retatrutide through its compassionate use program, a person must:<\/p>\n

[1]<\/p>\n

Be age 18 or older.Be unable to participate in a clinical trial.Have refractory obesity.Have at least two serious obesity-related complications.Have discussed all standard treatment options with a doctor.<\/p>\n

Refractory obesity means that sufficient weight loss hasn\u2019t occurred despite lifestyle changes and treatment, says\u00a0Yuval Pinto, MD<\/a>, an obesity and family medicine doctor at Johns Hopkins Medicine in Baltimore. Serious complications could include type 2 diabetes<\/a>, high blood pressure, heart disease<\/a>, heart failure, or certain heart rhythm disorders, he says.<\/p>\n

Kim points out that one part of the criteria remains unclear: What does it mean to have \u201cdiscussed\u201d all standard options?<\/p>\n

\u201cDoes this simply mean that available treatments have been reviewed with the patient, or does it require that they have actually tried them?\u201d Kim asks. \u201cIf it is the latter, would patients also be expected to undergo \u2014 or be deemed ineligible for \u2014 bariatric surgery<\/a> before qualifying? Clear guidance would be helpful.\u201d<\/p>\n

Only One U.S. Clinical Trial for Retatrutide Is Currently Recruiting<\/p>\n

While studies on retatrutide are still ongoing, the ones currently enrolling participants are not general obesity trials. As of August 4, 2026,\u00a0ClinicalTrials.gov<\/a> listed only one retatrutide trial recruiting participants, for people with high-risk metabolic dysfunction-associated steatotic liver disease<\/a>, the condition formerly known as nonalcoholic fatty liver disease.<\/p>\n

\u201cClinical trials aren\u2019t available in every region, leaving some patients with no realistic path to access the drug before approval,\u201d Kim says. Even when a trial is available, a person may not meet its requirements, or they may be randomly assigned to receive a placebo (dummy drug).<\/p>\n

How to Apply for Compassionate Use<\/p>\n

Patients cannot apply directly to Lilly for compassionate use of retatrutide. A treating doctor must support the request and contact the drugmaker. If Lilly agrees to supply the drug, authorization from the FDA and an institutional review board would also be required.<\/p>\n

Lilly\u2019s general expanded-access policy says that it will respond within five business days after receiving the required medical information, although the doctors interviewed by STAT described delays and little clarity about the process.<\/p>\n

[1]<\/p>\n

[7]<\/p>\n

Should You Ask Your Doctor About Compassionate Use Retatrutide?<\/p>\n

It may be reasonable to ask for compassionate use retatrutide if you have severe obesity with serious complications, have tried available treatments without enough improvement, and cannot join an appropriate clinical trial.<\/p>\n

\u201cIf I had tried everything and nothing helped, then yes, I would consider it as a last resort,\u201d Dr. Pinto says. \u201cBut it wouldn\u2019t be my first choice, because retatrutide isn\u2019t FDA-approved.\u201d<\/p>\n

Some doctors interviewed by STAT questioned whether Lilly would provide meaningful access beyond a small number of exceptional cases. Others said that they wanted more safety data before using retatrutide outside of the close monitoring of a clinical trial.<\/p>\n

[1]<\/p>\n

Lilly has not said how many requests it will approve, how long treatment would continue, or who would pay for related monitoring and care. That leaves a substantial gap between being potentially eligible and actually receiving the medication.<\/p>\n

\u201cI don\u2019t see compassionate use as a viable option for retatrutide for the majority of patients,\u201d says Kim.<\/p>\n

Compounded Retatrutide Remains Illegal (and Risky)<\/p>\n

Kim points out that some people are already obtaining retatrutide through unapproved channels like compounding pharmacies<\/a> \u2014 a decision that comes with significant risks.<\/p>\n

These products may contain the wrong amount, contaminants, or a different ingredient. Selling compounded retatrutide is also illegal. For these reasons, people should avoid products sold online as compounded or \u201cresearch\u201d retatrutide.<\/p>\n

[8]<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly, the drugmaker behind the GLP-1 drugs Mounjaro and Zepbound, will allow a limited number of adults…\n","protected":false},"author":2,"featured_media":803124,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[58],"tags":[97,243],"class_list":["post-803123","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/803123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=803123"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/803123\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/803124"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=803123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=803123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=803123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}